Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qingdao Vland Biotech Inc. (603739.SS)
Qingdao, CN
Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, animal vaccines, and veterinary health products. Its extensive product range features enzymes for animal feed, industrial uses, and food processing, along with various probiotics, such as aquaculture premixes, general health supplements, and both animal and plant-specific formulations. The company also provides a comprehensive array of animal vaccines and biological solutions, including both live and inactivated vaccines for poultry and swine, in addition to antibodies. Its offerings extend to poultry pharmaceuticals, covering antiparasitic, antiviral, and nutritional medications, alongside disinfectants. Furthermore, it supplies traditional Chinese veterinary remedies designed for aquatic species, poultry, and livestock, including laying hens. Vland Biotech's diverse clientele operates across numerous sectors, such as agriculture, animal husbandry, textile manufacturing, papermaking, household cleaning and detergents, food production, biofuel development, and environmental protection. This entity, established in 2005 and headquartered in Qingdao, China, operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -7.58% | -14.95% | -19.50% | -16.34% | -9.54% | -4.83% | -3.18% | -26.35% | +22.14% | +22.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+3.4% ★ Q1'26: +11.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+12.0% Q1'26: +76.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+2.0% Q1'26: +1.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+10.4% ★ Q1'26: +8.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.4% ★ Q1'26: +4.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.5% ★ Q1'26: +5.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.49× Q1'26: 6.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.15B
est: 1.16B (-0.5%)
|
1.16B
est: 1.20B (-2.7%)
|
1.20B
est: 1.28B (-6.4%)
|
1.32B
est: 1.27B (+3.9%)
|
1.37B
est: 1.45B (-5.8%)
|
1.51B
1.43B – 1.59B
+4.1% YoY
|
1.67B
1.54B – 1.80B
+10.6% YoY
|
1.85B
1.73B – 1.98B
+11.0% YoY
|
| EBITDA |
225.23M
est: 212.94M (+5.8%)
|
175.07M
est: 219.95M (-20.4%)
|
211.50M
est: 235.76M (-10.3%)
|
256.62M
est: 230.30M (+11.4%)
|
258.27M
est: 262.74M (-1.7%)
|
273.61M
258.30M – 288.91M
+4.1% YoY
|
302.60M
279.91M – 325.29M
+10.6% YoY
|
335.76M
313.64M – 357.87M
+11.0% YoY
|
| EBIT |
173.53M
est: 145.08M (+19.6%)
|
109.36M
est: 149.85M (-27.0%)
|
137.71M
est: 160.62M (-14.3%)
|
146.21M
est: 145.94M (+0.2%)
|
141.70M
est: 166.49M (-14.9%)
|
173.38M
163.68M – 183.08M
+4.1% YoY
|
191.75M
177.37M – 206.13M
+10.6% YoY
|
212.76M
198.75M – 226.77M
+11.0% YoY
|
| Net Income |
132.57M
est: 137.80M (-3.8%)
|
69.84M
est: 107.11M (-34.8%)
|
80.71M
est: 122.77M (-34.3%)
|
62.64M
est: 67.32M (-7.0%)
|
69.81M
est: 82.28M (-15.2%)
|
79.78M
72.94M – 86.62M
-3.0% YoY
|
84.77M
77.90M – 91.64M
+6.2% YoY
|
92.25M
84.35M – 100.15M
+8.8% YoY
|
| SGA |
283.25M
est: 191.38M (+48.0%)
|
295.56M
est: 197.68M (+49.5%)
|
311.42M
est: 211.89M (+47.0%)
|
340.27M
est: 292.85M (+16.2%)
|
183.63M
est: 334.09M (-45.0%)
|
347.91M
328.45M – 367.38M
+4.1% YoY
|
384.78M
355.92M – 413.63M
+10.6% YoY
|
426.94M
398.82M – 455.06M
+11.0% YoY
|
| EPS |
0.54
est: 0.55 (-1.8%)
|
0.28
est: 0.43 (-34.5%)
|
0.32
est: 0.49 (-34.7%)
|
0.25
est: 0.27 (-7.4%)
|
0.28
est: 0.33 (-15.2%)
|
0.32
0.29 – 0.35
-3.0% YoY
|
0.34
0.31 – 0.37
+6.3% YoY
|
0.37
0.34 – 0.40
+8.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gang Chen | GM & Chairman | — | male |
| Hailiang Li | Accounting Supervisor | — | — |
| Piyuan Qiao | Chief Financial Officer & Director | — | male |
| Xuemei Xu | Deputy General Manager | — | female |
| Yong Jiang | Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603739.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
